ArticleThe Lancet. Microbe2023
Biofilm formation and virulence potential of carbapenem-resistant Pseudomonas aeruginosa.
Article in The Lancet. Microbe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Evolving Triad of Carbapenem Resistance: Emergence of Dominant CRPA, Persistent CRAB, and Rebounding CRKP in a Chinese Regional Hospital (2020-2024).Infection and drug resistance · 2026Article
- A broad-host-range inhalable phage cocktail for treatment of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Biosynthetic ε-poly-L-lysine for the treatment of extensively- and pan-drug-resistant Pseudomonas aeruginosa.npj antimicrobials and resistance · 2025Article
- Dual-species proteomics and targeted intervention of animal-pathogen interactions.Journal of advanced research · 2025Article
- Mortality and exacerbations in bronchiectasis patients with carbapenem-resistant Pseudomonas aeruginosa isolation: a long-term retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2025Article
- Antibiotic-ResistantMicroorganisms · 2025Review
- Juglone as a Natural Quorum Sensing Inhibitor againstACS pharmacology & translational science · 2024Article
- Molecular epidemiology and carbapenem resistance mechanisms ofFrontiers in microbiology · 2024Article
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
37105205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.